TuHURA Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2012 | FY2011 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $20.5M | $13.3M | $9.4M | $1.6M | $1.1M |
| SG&A Expense | $7.6M | $3.9M | $4.1M | $1.2M | $241.8K |
| Operating Income | $-29.4M | $-17.5M | $29.3M | $-18.9K | $-33.1K |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $625.3K | $4.1M | $18.7K | $7.5K | $21.9K |
| Pretax Income | $-30.1M | $-21.7M | $29.3M | — | — |
| Income Tax Expense | $1.6K | $3.8K | $0 | — | — |
| Net Income | $-30.1M | $-21.7M | $-29.3M | $-2.4M | $-1.3M |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | $-0.63 | $-0.40 | $-0.82 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.63 | $-0.40 | $-0.82 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 47.9M | 56.0M | 35.7M | 903.1M | 1.71B |
| Shares Outstanding (Diluted) | 47.9M | 56.0M | 35.7M | 903.1M | 1.71B |
| Dividends Per Share | — | — | — | — | — |